- Home
- MREO vs QTRX Comparison
MREO vs QTRX Comparison
Compare MREO & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- QTRX
- Stock Information
- Founded
- MREO 2015
- QTRX 2007
- Country
- MREO United Kingdom
- QTRX United States
- Employees
- MREO N/A
- QTRX N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- QTRX Biotechnology: Laboratory Analytical Instruments
- Sector
- MREO Health Care
- QTRX Industrials
- Exchange
- MREO Nasdaq
- QTRX Nasdaq
- Market Cap
- MREO 482.5M
- QTRX 361.0M
- IPO Year
- MREO N/A
- QTRX 2017
- Fundamental
- Price
- MREO $2.50
- QTRX $7.11
- Analyst Decision
- MREO Strong Buy
- QTRX Strong Buy
- Analyst Count
- MREO 6
- QTRX 4
- Target Price
- MREO $7.83
- QTRX $23.25
- AVG Volume (30 Days)
- MREO 1.5M
- QTRX 671.4K
- Earning Date
- MREO 03-26-2025
- QTRX 05-06-2025
- Dividend Yield
- MREO N/A
- QTRX N/A
- EPS Growth
- MREO N/A
- QTRX N/A
- EPS
- MREO N/A
- QTRX N/A
- Revenue
- MREO $1,000,000.00
- QTRX $133,809,000.00
- Revenue This Year
- MREO N/A
- QTRX $13.89
- Revenue Next Year
- MREO N/A
- QTRX $14.79
- P/E Ratio
- MREO N/A
- QTRX N/A
- Revenue Growth
- MREO N/A
- QTRX 14.72
- 52 Week Low
- MREO $2.25
- QTRX $6.80
- 52 Week High
- MREO $5.02
- QTRX $27.37
- Technical
- Relative Strength Index (RSI)
- MREO 38.26
- QTRX 37.34
- Support Level
- MREO $2.39
- QTRX $7.16
- Resistance Level
- MREO $2.59
- QTRX $7.82
- Average True Range (ATR)
- MREO 0.17
- QTRX 0.49
- MACD
- MREO 0.02
- QTRX 0.05
- Stochastic Oscillator
- MREO 39.87
- QTRX 23.31
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.